Biocon is preparing to enter the fast-growing market for GLP-1 receptor agonists, a class of drugs used to treat diabetes and obesity that includes blockbusters such as Ozempic and Mounjaro, as the ...

Kiran Mazumdar Shaw has a number in her head: one in five. That is the share of global insulin users she wants to use a Biocon product—an aspiration the biotech billionaire shared during a media ...